Benign prostatic hyperplasia (BPH) is a progressive

disease commonly associated with bothersome lower

urinary tract symptoms (LUTS). It may result in

complications, such as acute urinary retention (AUR),

and require BPH-related surgery [1-3]. Combination

therapy with α-blockers and 5ARIs has been proven

effective in reducing LUTS, decreasing TPV, and

reducing the risk of disease progression compared to

treatment with a single medication or placebo [4-5].

Introduction

BPH patients with lower urinary tract symptoms

(LUTS) under combination therapy were

retrospectively analyzed from 1 to 12 years span. The

therapeutics effects were assessed by International

Prostatic Symptoms Score (IPSS) and quality of life

index (QoL-I), total prostatic volume (TPV), maximum

flow rate (Qmax), voided volume (VoL), prostatic

specific antigen (PSA) at baseline and annually. The

reason and predictors of discontinued combination

therapy were also investigated. Conclusion

Methods

Results

References

A total of 625 patients, aged 40-97 (mean, 73) years,

with 1-12 years of follow-up (mean, 3 years) were

retrospectively enrolled. All measured parameters

showed significant improvement after combination

therapy. Three hundred and sixty-nine (59%) patients

discontinued combination therapy with mean

treatment duration of 2.2 years. The most common

reason for discontinuation of combination therapy was

conversion to single medication (19.8%). Age and QoL-

1 did not influence the adherence rate, but the larger

Qmax and larger TPV lead to better adherence to

combination therapy.

Results (Continued)

LONG-TERM COMBINED α –BLOCKERS AND 5- α –REDUCTASE INHIBITOR IN BPH-THERAPEUTIC EFFECTS, ADHERENCE, AND

PREDICTORS FOR WITHDRAWAL OF MEDICATION

Hueih-Ling Ong1, Chun-Hou Liao2, Hann-Chorng Kuo1

Department of Urology1, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan Department of Urology2, Cardinal Tien Hospital and Fu-Jen Catholic University, New Taipei, Taiwan

1. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of

benign prostatic hyperplasia. Urology 2001;58:5-16.

2. Emberton M, Fitzpratick JM, Garcia-Losa M, Qizilbash N,

Djavan B. Progression of benign prostatic hyperplasia:

systemic review of the placebo arms of clinical trials.

BJU Int 2008;102:981-6.

3. Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gómez

JM, Castro R. Benign prostatic hyperplasia as a

progressive disease: a guide to the risk factors and

options for medical management. Int J Clin Pract. 2008

Jul;62(7):1076-86.

4. McConnell JD, Roehrborn CG, Bautista OM, et al. The

long-term effect of doxazosin, finasteride, and

combination therapy on the clinical progression of

benign prostatic hyperplasia. Medical Therapy of

Prostatic Symptoms (MTOPS) Research Group. N Engl J

Med. 2003;18:2387-2398.

5. Roehrborn CG, Siami P, Barkin J, et al. CombAT Study

Group. The effects of combination therapy with

dutasteride and tamsulosin on clinical outcomes in men

with symptomatic benign prostatic hyperplasia: 4-year

results from the CombAT study. Eur Urol. 2010;57:123-

131.

Patients receiving combination therapy showed

significant improvement in all measured

parameters. The most common cause of

discontinuation of combination therapy was

conversion to single medication. The larger Qmax

and larger TPV after treatment predicted patient

adherence to combination therapy.

108